Rodrigues, J. C. L., Erdei, T., Ghosh Dastidar, A., McIntyre, B., Burchell, A. E., Ratcliffe, L. E. K., Hart, E. C. J., Hamilton, M. C. K., Paton, J. F. R., Nightingale, A. K., & Manghat, N. E. (2017). Electrocardiographic detection of hypertensive left atrial enlargement in the presence of obesity: re-calibration against cardiac magnetic resonance. *Journal of Human Hypertension*, 31(3), 212–219. <https://doi.org/10.1038/jhh.2016.63>

Peer reviewed version

Link to published version (if available):
[10.1038/jhh.2016.63](https://doi.org/10.1038/jhh.2016.63)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Nature at <http://www.nature.com/jhh/journal/vaop/ncurrent/full/jhh201663a.html>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Title

Electrocardiographic detection of hypertensive left atrial enlargement in the presence of obesity: re-calibration against cardiac magnetic resonance.

Running Title

Obesity and detecting left atrial enlargement

Authors

Jonathan C. L Rodrigues BSc(Hons), MBChB(Hons), MRCP, FRCR^{1,2}

Tamas Erdei MD, PhD¹

Amardeep Ghosh Dastidar MBChB, MRCP¹

Bethannie McIntyre BA, MBBS³

Amy E. Burchell BA, MB BCh, MRCP⁴

Laura E. K. Ratcliffe BSc(Hons), MBBS, MRCP⁴

Emma C. Hart BSc, PhD^{2,4}

Mark C. K. Hamilton MBChB, MRCP, FRCR¹

Julian F. R. Paton BSc(Hons), PhD^{2,4}

Angus K. Nightingale MA, MB BChir, FRCP, MD^{2,4}

Nathan E. Manghat MBChB, MRCP, FRCR, MD¹

Affiliations

¹ NIHR Bristol Cardiovascular Biomedical Research Unit, Cardiac Magnetic Resonance

Department, Bristol Heart Institute, University Hospitals Bristol NHS Foundation

Trust, Upper Maudlin Street, Bristol, BS2 8HW

² School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Medical Sciences Building, University Walk, Bristol, BS8 1TD

³ Severn Postgraduate Medical Education Foundation School, NHS Health Education South West, Deanery House, Vantage Office Park, Bristol, BS16 1GW

⁴ CardioNomics Research Group, Clinical Imaging and Research Centre, Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8HW

Corresponding author

Dr. Jonathan C L Rodrigues

NIHR Bristol Cardiovascular Biomedical Research Unit, Cardiac Magnetic Resonance Department, Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8HW

Telephone: +44 117 342 5888

Fax: +44 117 342 5526

Email: jonrodrigues@doctors.org.uk

Acknowledgments: This work was part-funded by the NIHR Bristol Cardiovascular Biomedical Research Unit, Bristol Heart Institute. We thank Mr Christopher Lawton, CMR Superintendent Radiographer, and the CMR radiographer team within in the Bristol Heart Institute for their expertise in acquiring the CMR studies. The views expressed in this manuscript are those of the authors and not necessarily reflect those of the National Health Service, National Institute for Health Research, or

Department of Health. JCLR is funded by the Clinical Society of Bath Postgraduate Research Bursary 2014 and Royal College of Radiologists Kodak Research Scholarship 2014. ECH (BHF grant IBSRF FS/11/1/28400) and JRFP are both funded by the British Heart Foundation.

Key words: Obesity, ECG; Electrocardiograph; Left atrial enlargement; Hypertension; Cardiac magnetic resonance

Conflict of interest: None.

Abstract

Left atrial enlargement (LAE) has adverse prognostic implications in hypertension.

We sought to determine the accuracy of 5 ECG criteria for LAE in hypertension relative to cardiac magnetic resonance (CMR) gold-standard, and investigate the effect of concomitant obesity. 130 consecutive patients (age: 51.4 ± 15.1 years, 47% male, 51% obese, systolic blood pressure: 171 ± 29 mmHg, diastolic blood pressure: 97 ± 15 mmHg) referred for CMR (1.5T) from a tertiary hypertension clinic were included. Patients with concomitant cardiac pathology were excluded. ECGs were assessed blindly for: 1) P wave >110 ms, 2) P mitrale, 3) P wave axis $<30^\circ$, 4) Area of negative P terminal force in V1 >40 ms·mm and 5) Positive P terminal force in aVL >0.5 mm. LA volume ≥ 55 ml/m², measured blindly by CMR, was defined as LAE.

Sensitivity, specificity, positive predictive value, negative predictive value, accuracy and area under the receiver operator curve were calculated. The prevalence of LAE by CMR was 26%. All the individual ECG LAE criteria were more specific than sensitive, with specificities ranging from 70% (P axis $<30^\circ$) to 99% (P mitrale). Obesity attenuated the specificity of most of the individual ECG LAE criteria. Obesity correlated with significant lower specificity (48% vs 65%, $P < 0.05$) and a trend towards lower sensitivity (59% vs 43%, $P = 0.119$) when ≥ 1 ECG LAE criteria were present. Individual ECG criteria of LAE in hypertension are specific, but not sensitive, at identifying LAE. The ECG should not be used to excluded LAE in hypertension, particularly in obese subjects.

Introduction

The 2013 joint European Society of Cardiology and European Society of Hypertension guidelines for the management of arterial hypertension advise that a 12-lead electrocardiogram (ECG) should be acquired for all patients with hypertension(1).

The ECG can show evidence of left atrial enlargement (LAE), which is an important predictor of cardiovascular mortality and morbidity. Indeed, performing an ECG in all subjects with hypertension is advised by the American Society of Hypertension and International Society of Hypertension (ASH/ISH) in their joint clinical practice guidelines, at least in part to assess for LAE(2). LAE has been demonstrated to be a marker of left ventricular (LV) diastolic dysfunction(3) and a predictor of the development of atrial fibrillation(4), congestive heart failure(5), stroke(6), myocardial infarction(7) and cardiac mortality(8). Detecting of LAE is therefore important in subjects with hypertension. All subjects with hypertension should have an ECG performed. LAE can be demonstrated on ECG. The first line imaging modality to structurally assess the heart in hypertension is the echocardiogram and this can be used to gauge the left atrial size. To date, LAE ECG criteria have been assessed against two-dimensional (2D) echocardiography reference standards(9)(10) (11)(12). However, echocardiographic measurements may be inaccurate due to limited acoustic windows and variation in image acquisition planes. This may be particularly troublesome in obesity subjects, with is a common comorbidity in subjects with hypertension. Furthermore, since the left atrium (LA) is not spherical, the assumption of a constant radius necessary for the M-mode or some 2D echocardiography measurements, e.g. the ellipsoid method, does not hold true, limiting the accuracy(13). Cardiac magnetic resonance imaging (CMR) has superior

spatial resolution compared to echocardiography and can consistently acquire LA images regardless of patient body habitus and, for these reasons, CMR is considered gold-standard for atrial assessment. Yet, there are few studies investigating the diagnostic performance of ECG LAE criteria against CMR. Furthermore, those existing studies were either in unselected subjects undergoing CMR and not in the context of hypertension(14) or have used an indexed LA volume of $>28\text{ml/m}^2$ to define LAE(15), which is from the echocardiogram literature(16) and is significantly lower than LA volume of 55ml/m^2 which is 2 standard deviation measurements above the mean of normal, healthy subjects from published CMR studies(17)(18)(19)(20). Thus, to date, ECG LAE criteria appear to have been validated against a variety of reference standards. As the ECG is often the first diagnostic investigation performed when assessing for LAE in hypertensive patients, and treatment decisions may be made on its results, understanding the diagnostic performance of the ECG at detecting LAE relative to CMR gold-standard in a cohort of hypertensive subjects is important.

Obesity and hypertension are common co-morbidities. The former has also been associated with LAE(21). However, to the best of our knowledge, no previous study has investigated the impact of obesity on the diagnostic performance of the ECG at detecting LAE. Consequently, our aim was to comprehensively evaluate the diagnostic performance of 5 ECG criteria for the detection of LAE, in a cohort of hypertensive patients with high LAE prevalence, relative to CMR derived measurements of LA volume. Additionally, we sought to determine the effect of obesity on the diagnostic performance of the ECG at detecting LAE.

Methods

Study population

In our institution, CMR is used routinely in the tertiary hypertension clinic setting to detect hypertensive end-organ damage and screen for potential secondary causes of hypertension(22). In this prospective study, we included all eligible, consecutive hypertensive patients referred for a CMR from the Bristol Heart Institute tertiary hypertension clinic, which has a catchment area of the South West of England, between January 2011 and February 2015 (**Figure 1**). Subjects were excluded from analysis if they exhibited any concomitant cardiac pathology, which could confound the aetiology of LAE, such as previous myocardial infarction, other cardiomyopathy and/or moderate-severe valvular heart disease.

Demographic and baseline clinical data were documented. The World Health Organization definition of obesity of body mass index (BMI) $> 30\text{kg/m}^2$ was used(23). The mean office systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were from repeated readings from both arms, where available, recorded with an appropriately-sized BP cuff at the time of ECG acquisition, following a period of 5 minutes seated rest.

Subjects provided written consent for their images to be used for research.

The study conformed to the governance arrangements for research ethics committees (REC).

ECG

A standard 12-lead ECG (scale: 10mm = 1mV, speed: 25 mm/s) was recorded supine, during quiet respiration. The analyzing clinician was blinded to all other CMR and clinical data. The presence of complete bundle branch block was an exclusion criterion. The 5 ECG LAE criteria evaluated were: 1) P wave >110ms, 2) P mitrale (notched P wave with inter-peak duration >40ms), 3) P wave axis <30°, 4) Area of negative P terminal force in lead V1 (NPTF-V1) > 40ms·mm and 5) Positive P terminal force in aVL (PPTF-aVL) >0.5mm(9)(24)(12)(25).

CMR protocol

CMR was performed with the subjects lying supine at 1.5T (Avanto, Siemens, Erlangen, Germany), with anterior 8-element and posterior 8-element body-array coils. Steady state free precession (SSFP) cines were acquired (Time to echo 1.07ms, temporal resolution 38.1ms, in-plane pixel size 2.0 x 2.0mm, matrix 156 x 192) with retrospective ECG-gating and breath-holding. The entire LV was imaged with short axis SSFP with slice thickness of 8mm and no slice gap. The standard 3 long-axis cines (4-chamber, 2-chamber and 3-chamber) were acquired at 60 degrees from each other. Additionally, late gadolinium myocardial enhancement (LGE) imaging was routinely acquired using an inversion-recovery fast gradient echo sequence, as well as a phase-sensitive inversion-recovery sequence, 10-15 minutes following 0.1mmol/kg intravenous gadobutrol (Gadovist, Bayer Pharma AG, Germany). Inversion times were optimized in each patient to ensure adequate nulling of normal myocardium. Subjects with subendocardial LGE consistent with previous MI were excluded.

CMR analysis

All CMR analysis was performed blinded to all other clinical and ECG data by an experienced CMR reader using dedicated CMR post-processing software (CMR42, Circle Cardiovascular Imaging Inc., Calgary, Canada). Maximum left atrial (LA) volume was measured at maximal atrial dilatation at left ventricular end-systole, as previously described (**Figure 2**)(14)(26). Briefly, maximum LA volume was defined as the image immediately preceding the opening of the mitral valves on SSFP cines. LA length was measured at maximum atrial dilatation from the posterior LA wall to the level of the mitral valve plane, parallel to the long-axis of the heart, in the 2-chamber and 4-chamber SSFP cines. The endocardial board of the LA was manually contoured at maximum atrial diastole in the apical 2-chamber and 4-chamber SSFP cines. The confluence of the pulmonary veins and LA appendage were excluded from planimetry measurements. The left atrial borders were delimited at the planes of the AV annulus and the junctions of venous inflow. LA volume was then calculated according to the biplane area-length method and then indexed to body surface area (BSA)(16)(27)(28), calculated using the Mosteller formula. LAE was defined as $\geq 55\text{ml/m}^2$ which is 2 standard deviation measurements above the mean of normal, healthy subjects from published CMR studies(17)(18)(19)(20).

LVM was measured as described previously(29)(30). In brief, LV endocardial contours were generated on the short axis SSFP cines stack at end-diastole using previously validated(31) blood-pool threshold detection software (CMR42, Circle Cardiovascular Imaging Inc., Calgary, Canada). Epicardial contours were manually plotted. LVM was

derived by multiplying total myocardial volume, inclusive of trabeculae and papillary muscles, by myocardial specific gravity (1.05 g/ml), as previously described(29). LVM was indexed to BSA. Left ventricular hypertrophy (LVH) was defined as LVM/BSA >95th percentile of established CMR reference ranges (women = 77-78g/m² and men = 89-93g/m²)(29).

Statistical analysis

All statistical analyses were performed in SPSS (v.21, Armonk, NY, USA: IBM Corp).

Using the pooled prevalence of LAE of 32% from a recent systematic review of 10,141 subjects assessed by echocardiogram(32), an alpha error of 0.05 and a statistical power of 90%, the sample size for our study, accounting for the fact that CMR has been demonstrated to reduce the sample sizes by 6-fold compared to 2D echocardiogram when a power of 90% is employed(33), should be 100.

Consequently, our final sample size of 130 subjects, from an initial 160 subjects who were screened, was sufficient for this study. Normally-distributed continuous variables were expressed as mean $\pm$ standard deviation and compared using unpaired Student's T test or one-way analysis of variance with *post-hoc* correction for multiple testing as appropriate. Categorical variables were expressed as percentages and interrogated with the Fisher's exact test. Specificity, sensitivity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were also calculated. Area under the receiver-operating curve (AUC-ROC) analysis was performed and to compare the diagnostic performance of the various ECG criteria. R values are for Pearson's correlation coefficient. Multivariate logistic regression

analysis was performed to identify independent predictors of ECG false positives and false negatives of LAE relative to CMR. Statistical significance was set at $P < 0.05$.

Results

Demographics

One hundred and sixty consecutive patients referred for CMR were assessed for eligibility. Thirty patients met the exclusion criteria (**Figure 1**), resulting in a final sample size of 130 (men: 47%, age: 51 ± 15 years). CMR evidence of LAE was present in 26% ($n = 34$) and obesity was present in 51% ($n = 67$) of the cohort. There were no significant differences between non-obese and obese cohorts for the following variables: age, gender, office SBP, office DBP, treatment with angiotensin converting enzyme inhibitor / angiotensin II receptor blocker or calcium channel blocker (**Table 1**).

Diagnostic performance of ECG criteria of LAE

Specificity was higher than sensitivity for all ECG LAE criteria (**Table 2**). Specificities ranged from 70% to 99% for the individual ECG criteria of LAE. However, the sensitivities ranged from 0% to 18% and the best performance on AUC-ROC was 0.502 (95th CI: 0.389 – 0.616) for PPTF-aVL > 0.5 mm. A composite ECG criterion consisting of any positive individual ECG criteria for LAE had the highest sensitivity of 29% but a specificity of 48% and accuracy of 43%.

Obesity subgroup analysis of diagnostic performance of ECG criteria for LAE

The specificity was significantly lower in obese subjects compared to non-obese subjects for P wave $< 30^\circ$ (non-obese: 83% vs obese: 64%, $P < 0.05$) and for the composite ECG criterion consisting of any positive individual ECG criteria (non-obese: 65% vs obese: 48%, $P < 0.05$) (**Table 3**). There were non-significant trends for lower specificity for NPTF-V1 > 40 ms.mm (non-obese: 89% vs obese: 78%, $P = 0.06$) and PPTF-aVL > 0.5 mm (non-obese: 96% vs obese: 88%, $P = 0.07$) for obese compared to non-obese subjects.

The AUC-ROC values were lower for all ECG criteria of LAE and for the composite ECG criterion consisting of any positive individual ECG criteria for obese subjects compared to non-obese subjects (**Table 3**).

Indexed LA size in subjects with positive ECG criteria

The mean indexed LAV were not significantly different between those subjects with positive ECGs compared to negative ECGs for all the ECG criteria for LAE investigated (**Table 4**). There was no correlation between the number of positive ECG criteria and absolute LAV ($R = -0.05$, $P = 0.66$) or index LAV ($R = -0.09$, $P = 0.4$). However, in obesity subgroup analysis, there were consistent trends towards larger absolute and indexed LAV in obese subjects who did not fulfill ECG criteria for LAE compared to obese subjects who did fulfill ECG criteria for LAE. In addition, obese subjects who did not fulfill ECG criteria for LAE had significantly large absolute LAV compared to similar non-obese subjects but these significant differences no longer persisted after indexing the LAV to BSA.

Prevalence of LAE in subjects without hypertensive left ventricular hypertrophy

Of the 130 hypertensive subjects, 35% (46/130) had LVH and 65% (84/130) did not have LVH. LAE occurred in 19% (16/84) of subjects without LVH. However, the prevalence of LAE amongst subjects with LVH (39%, 18/46) was significantly higher than amongst subjects without LVH (LAE and LVH: 39% vs LAE and no LVH: 19%, $P < 0.05$).

Predictors of false positive ECG criteria for LAE

Multivariate logistic regression analyses, accounting for age, gender and BMI, were performed to identify predictors of false positive and false negative ECGs for LAE (**Table 5**). For P wave axis $< 30^\circ$, female gender and increasing BMI were significant independent predictors of false positive ECGs for LAE relative to CMR gold-standard. Age, gender and BMI were not predictors of false negative ECGs for LAE.

Discussion

For the first time, we investigate the impact of obesity on the diagnostic performance of the ECG at detecting LAE as compared to CMR gold-standard in subjects with arterial hypertension.

We demonstrate that all the ECG criteria for LAE are poor at excluding LAE relative to CMR. Consequently, a normal ECG in a hypertensive patient has a high chance of being falsely reassuring for an absence of LAE, and is less specific for LAE in the presence of obesity. LAE is a marker of left ventricular (LV) diastolic dysfunction(3)

and a predictor for the development of atrial fibrillation(4), congestive heart failure(5), stroke(6), myocardial infarction(7) and cardiac mortality(8). Failing to identify LAE may alter an individual's cardiovascular risk estimation and theoretically could have treatment implications(1). Furthermore, in subgroup analysis of the LIFE study, Wachtell et al. found that prevention of AF during antihypertensive treatment may be improved by antihypertensive therapy that reduces LA size in addition to controlling blood pressure(34) and the effect of different antihypertensive agents on LA size has been previously been investigated(35).

The sensitivity of the ECG at excluding LAE has varied from 6 to 69% relative to echocardiography in previous studies(9)(10)(11)(12)(36). Regarding individual ECG criteria, we found higher sensitivity for P wave >110ms compared to previous echocardiographic studies(9)(10)(12)(25). We demonstrate higher sensitivity for P mitrale and NPTF-V1 > 40ms·mm compared to the most recent echocardiographic study of 261 randomly selected patients, which calculated LAV using a similar bi-plane atrial volume analysis from 2-dimensional echocardiography(36). Our findings are similar to those of Tsao et al. who performed ECG-CMR correlation, albeit in unselected patients(14).

However, it should be realized that a direct comparison between existing echocardiography studies and our work is prone to discrepancy. Estimation of atrial size with echocardiography, both by M-mode and 2-dimensional techniques, may be limited by poor acoustic windows and limited spatial resolution, which may underestimate left atrial dimensions. Indeed, the atrial size measured by CMR

measurement are recognized to exceed echocardiograph measurements of LAV by 14-37%(37)(38). As a result, the thresholds and accuracy for defining LAE will differ between studies using CMR and echocardiography as the gold-standard for LAV and, therefore, the proportion of individuals classified as having LAE will also differ which will impact on sensitivity and specificity analyses. Furthermore, differing allometric scaling of LAV between studies may be another important variable.

Whilst the ECG criteria generally have a high specificity for identifying LAE, we show for the first time that the diagnostic performance falls in the presence of obesity. This is potentially an important finding with clinical implications. The MONIC/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study of 1,212 participants demonstrated that whilst both hypertension and obesity were predictors of LAE, obesity was numerically stronger(39). Furthermore, obesity hypertensive subjects had the largest indexed LAV(39). The lower specificity of the ECG at identifying LAE relative to CMR in our study in obese subjects to non-obese subjects means that the ECG risks missing LAE in subjects are at a particular high risk for LAE. A putative reason why the ECG is less able to detect enlarged atria in obese subjects is due to electrical insulating effects of excess subcutaneous adipose tissue, a phenomenon which has previously been postulated to explain the effect of obesity on reducing the diagnostic performs of the ECG at detecting left ventricular hypertrophy(40)(41). Imaging obese hypertensive subjects with echocardiography to establish a diagnosis of LAE may also be difficult because adipose tissue can attenuate the ultrasonic beam and reduce the diagnostic quality of the study.

In terms of the clinical implications of our study, we suggest that the ECG should still remain the initial investigation of choice for assessing for LAE as advised in International guidelines(1)(2). However, clinicians should take into account the patient's BMI when interrogating the ECG for LAE. For example, we show that the positive predictive value is significantly lower in obese hypertensive subjects compared to non-obese subjects for P axis $< 30^\circ$ and PPTF-aVL $> 0.5\text{mm}$. The sensitivity of the investigation is also poor for both obese and non-obese subjects. It is clearly not practicable to perform CMR in all subjects with hypertension. Clinicians should consider investigating hypertensive patients with an additional modality, such as echocardiography in the first instance, to confirm the presence of LAE in obese subjects with positive P axis $< 30^\circ$ and PPTF-aVL $> 0.5\text{mm}$ criteria and in subjects where exclusion of LAE is important and may have therapeutic implications, for example in subjects with no other evidence of end-target damage where the demonstration of LAE would alter the cardiovascular risk sufficiently to alter treatment(1).

Finally, it is important to recognize that abnormalities in atrial conduction, and hence the electric sign recorded from the atria on the ECG in the form of the P wave can be independent of atrial size(42)(43). Multiple aetiologies may manifest with similar P wave abnormalities on ECG. As a result, in unselected populations, the ECG is unlikely to have good specificity for LAE as the changes may simply represent atrial abnormality rather than enlargement.

Limitations

Our clinical cohort study had a modest sample size of 130 patients. However, the increased accuracy and reproducibility of CMR relative to echocardiography increases the statistical power of the study. Furthermore, our study was in a selected population of well-characterised hypertensive subjects, and excluded patients with other concomitant cardiac pathology. Consequently, our results are more applicable to the hypertension community than most of the previous studies that have been in unselected populations.

We do not routinely estimate total body fat mass in our clinical practice and this variable could not be investigated. BMI has been used as a routinely recorded clinical surrogate. Theoretically, an increase in lean muscle mass could yield a BMI value in the obesity range but this is unlikely to have occurred in our cohort of patients.

In this non-invasive study, we were unable to adjust for certain variables that may alter P wave morphology, e.g. atrial pressure(43). The diagnostic accuracy of the ECG at detecting left ventricular hypertrophy in hypertension was not investigated in this study, but has been recently described(30).

Conclusion

We have recalibrated 5 ECG criteria for LAE against current non-invasive gold-standard CMR. The individual ECG criteria are more specific than sensitive at identifying anatomical LAE relative to CMR. However, the concomitant presence of obesity reduces the specificity for most ECG criteria for LAE. Clinicians need to be

aware of these differences when interpreting the ESC/ESH and ASH/ISH guidelines and tailor the ECG criteria they use accordingly taking into account the patient's BMI. Whilst the ECG may identify LAE, it has poor sensitivity and therefore the ECG should not be used in isolation to exclude LAE where this could have treatment implications. Obese hypertensive subjects are at risk of false positive and false negative results if the ECG is used to screen for LAE.

Conflicts of interest

None to declare

Summary Table

What is known about the topic

- 1) Detecting LAE in hypertension has prognostic and treatment implications.
- 2) The ECG can detect LAE and it has been validated against echocardiographic assessment of LA size.
- 3) The impact of obesity on the ECG detection of LAE has not previously been investigated.

What this study adds

- 1) We recalibrate 5 ECG criteria for LAE against non-invasive gold-standard CMR.
- 2) We show the ECG is more specific than sensitive at detecting LAE and that obesity reduces ECG specificity at detecting LAE.
- 3) We identify predictors of false positive and false negative ECG results with multivariate logistic regression analysis.
- 4) In hypertension, the ECG should not be used to exclude LAE

LAE = left atrial enlargement. ECG = electrocardiograph. LA = left atrial M = left ventricular mass. CMR = cardiac magnetic resonance.

References

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013 Jul;34(28):2159–219.
2. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community. *J Clin Hypertens*. 2014 Jan;16(1):14–26.
3. Alsaileek AA, Osranek M, Fatema K, McCully RB, Tsang TS, Seward JB. Predictive value of normal left atrial volume in stress echocardiography. *J Am Coll Cardiol*. 2006 Mar 7;47(5):1024–8.
4. Gerds E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Hypertension*. 2002 Mar 1;39(3):739–43.
5. Tsang TSM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients ≥ 65 years of age with abnormal left ventricular diastolic relaxation. *Am J Cardiol*. 2004 Jan 1;93(1):54–8.
6. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, et al. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. *Mayo Clin Proc*. 2004 Aug;79(8):1008–14.

7. Tsang TSM, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol*. 2006 Mar 7;47(5):1018–23.
8. Modena MG, Muia N, Sgura FA, Molinari R, Castella A, Rossi R. Left atrial size is the major predictor of cardiac death and overall clinical outcome in patients with dilated cardiomyopathy: a long-term follow-up study. *Clin Cardiol*. 1997 Jun;20(6):553–60.
9. Hazen MS, Marwick TH, Underwood DA. Diagnostic accuracy of the resting electrocardiogram in detection and estimation of left atrial enlargement: an echocardiographic correlation in 551 patients. *Am Heart J*. 1991 Sep;122(3 Pt 1):823–8.
10. Munuswamy K, Alpert MA, Martin RH, Whiting RB, Mechlin NJ. Sensitivity and specificity of commonly used electrocardiographic criteria for left atrial enlargement determined by M-mode echocardiography. *Am J Cardiol*. 1984 Mar 1;53(6):829–32.
11. van Dam I, Roelandt J, Robles de Medina EO. Left atrial enlargement: an electrocardiographic misnomer? An electrocardiographic-echocardiographic study. *Eur Heart J*. 1986 Feb;7(2):115–7.
12. Waggoner AD, Adyanthaya A V, Quinones MA, Alexander JK. Left atrial enlargement. Echocardiographic assessment of electrocardiographic criteria. *Circulation*. 1976 Oct;54(4):553–7.
13. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and

- in research studies to determine left atrial size. *Am J Cardiol.* 1999 Oct 1;84(7):829–32.
14. Tsao CW, Josephson ME, Hauser TH, O'Halloran TD, Agarwal A, Manning WJ, et al. Accuracy of electrocardiographic criteria for atrial enlargement: validation with cardiovascular magnetic resonance. *J Cardiovasc Magn Reson.* 2008 Jan;10:7.
 15. Bureekam S, Boonyasirinant T. Accuracy of left atrial enlargement diagnosed by electrocardiography as compared to cardiac magnetic resonance in hypertensive patients. *J Med Assoc Thai.* 2014 Mar;97 Suppl 3:S132–8.
 16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. *Eur J Echocardiogr.* 2006 Mar;7(2):79–108.
 17. Järvinen VM, Kupari MM, Hekali PE, Poutanen VP. Right atrial MR imaging studies of cadaveric atrial casts and comparison with right and left atrial volumes and function in healthy subjects. *Radiology.* 1994 Apr;191(1):137–42.
 18. Järvinen VM, Kupari MM, Poutanen VP, Hekali PE. Right and left atrial phasic volumetric function in mildly symptomatic dilated and hypertrophic cardiomyopathy: cine MR imaging assessment. *Radiology.* 1996 Feb;198(2):487–95.
 19. Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB. Atrial and ventricular volume and function in persistent and permanent atrial fibrillation, a magnetic resonance imaging study. *J Cardiovasc Magn Reson.* 2005 Jan;7(2):465–73.

20. Tseng W-YI, Liao T-Y, Wang J-L. Normal systolic and diastolic functions of the left ventricle and left atrium by cine magnetic resonance imaging. *J Cardiovasc Magn Reson*. 2002 Jan;4(4):443–57.
21. Movahed MR, Saito Y. Obesity is associated with left atrial enlargement, E/A reversal and left ventricular hypertrophy. *Exp Clin Cardiol*. 2008 Jan;13(2):89–91.
22. Rodrigues JCL, Amadu AM, Dastidar AG, Hassan N, Lyen SM, Lawton CB, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging*. 2015 Dec 24;
23. WHO | Obesity and overweight. World Health Organization;
24. Perosio AM, Suarez LD, Torino A, Llera JJ, Ballester A, Roisinblit JM. Reassessment of electrovectorcardiographic signs of left atrial enlargement. *Clin Cardiol*. 1982 Dec;5(12):640–6.
25. Ikram H, Drysdale P, Bones PJ, Chan W. The non-invasive recognition of left atrial enlargement: comparison of electro- and echocardiographic measurements. *Postgrad Med J*. 1977 Jul;53(621):356–9.
26. Kaminski M, Steel K, Jerosch-Herold M, Khin M, Tsang S, Hauser T, et al. Strong cardiovascular prognostic implication of quantitative left atrial contractile function assessed by cardiac magnetic resonance imaging in patients with chronic hypertension. *J Cardiovasc Magn Reson*. BioMed Central Ltd; 2011 Jan;13(1):42.

27. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. *J Cardiovasc Magn Reson*. 2005 Jan;7(5):775–82.
28. Sievers B, Kirchberg S, Addo M, Bakan A, Brandts B, Trappe H-J. Assessment of left atrial volumes in sinus rhythm and atrial fibrillation using the biplane area-length method and cardiovascular magnetic resonance imaging with TrueFISP. *J Cardiovasc Magn Reson*. 2004 Jan;6(4):855–63.
29. Maceira A, Prasad S, Khan M, Pennell D. Normalized Left Ventricular Systolic and Diastolic Function by Steady State Free Precession Cardiovascular Magnetic Resonance. *J Cardiovasc Magn Reson*. 2006 Jul 1;8(3):417–26.
30. Rodrigues JCL, McIntyre B, Dastidar AG, Lyen SM, Ratcliffe LE, Burchell AE, et al. The effect of obesity on electrocardiographic detection of hypertensive left ventricular hypertrophy: recalibration against cardiac magnetic resonance. *J Hum Hypertens*. 2016 Mar;30(3):197–203.
31. Childs H, Ma L, Ma M, Clarke J, Cocker M, Green J, et al. Comparison of long and short axis quantification of left ventricular volume parameters by cardiovascular magnetic resonance, with ex-vivo validation. *J Cardiovasc Magn Reson*. 2011 Jan;13(1):40.
32. Cuspidi C, Rescaldani M, Sala C. Prevalence of echocardiographic left-atrial enlargement in hypertension: a systematic review of recent clinical studies. *Am J Hypertens*. 2013 Apr;26(4):456–64.

33. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. *Hypertension*. 2002 Mar 1;39(3):750–5.
34. Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. *Blood Press*. 2010 Jun;19(3):169–75.
35. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. *Circulation*. 1998 Jul 14;98(2):140–8.
36. Lee KS, Appleton CP, Lester SJ, Adam TJ, Hurst RT, Moreno CA, et al. Relation of electrocardiographic criteria for left atrial enlargement to two-dimensional echocardiographic left atrial volume measurements. *Am J Cardiol*. 2007 Jan 1;99(1):113–8.
37. Anderson JL, Horne BD, Pennell DJ. Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2005 Jan;7(4):671–5.
38. Rodevan O, Bjornerheim R, Ljosland M, Maehle J, Smith HJ, Ihlen H. Left atrial volumes assessed by three- and two-dimensional echocardiography compared to MRI estimates. *Int J Card Imaging*. 1999 Oct;15(5):397–410.
39. Stritzke J, Markus MRP, Duderstadt S, Lieb W, Luchner A, Döring A, et al. The

- aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J Am Coll Cardiol*. 2009 Nov 17;54(21):1982–9.
40. Horton JD, Sherber HS, Lakatta EG. Distance correction for precordial electrocardiographic voltage in estimating left ventricular mass: an echocardiographic study. *Circulation*. 1977 Mar;55(3):509–12.
 41. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. *Circulation*. 1990 Mar;81(3):815–20.
 42. Di Bianco R, Gottdiener JS, Fletcher RD, Pipberger H V. Left atrial overload: a hemodynamic, echocardiographic, electrocardiographic and vectorcardiographic study. *Am Heart J*. 1979 Oct;98(4):478–89.
 43. Josephson ME, Kastor JA, Morganroth J. Electrocardiographic left atrial enlargement. Electrophysiologic, echocardiographic and hemodynamic correlates. *Am J Cardiol*. 1977 Jun;39(7):967–71.

Figure legends

Figure 1. A flow chart demonstrating the study exclusion criteria and final sample size (n = 130). *Image artifact from implantable loop recorder device precluding volumetric assessment from LV short axis SSFP cine stack. CMR = cardiac magnetic resonance, MI = myocardial infarction (defined as subendocardial late gadolinium

enhancement on CMR), HOCM = hypertrophic obstructive cardiomyopathy (clinical and/or CMR diagnosis), LVNC = left ventricular non-compaction cardiomyopathy (CMR diagnosis), DCM = idiopathic dilated cardiomyopathy (CMR diagnosis), Mod AR = moderate aortic regurgitation, AVR = aortic valve replacement.

Figure 2. Cardiac magnetic resonance measurements from steady state free precession cine images of the maximal left atrial area (A1) and the length of LA (L1) on 4C-cine (A) and area (A2) and length (L2) on 2C-cine (B). Left atrial volume= $8/3\pi[(A1)(A2)/L]$, where L is the shortest of either L1 or L2.

**Hypertensive patients referred for CMR
(n = 160)**

**Exclusion
criteria**

Patient factors

- Claustrophobia (n = 2)
- Body habitus (n = 3)

Ischaemic heart disease

- Previous MI (n = 10)

Cardiomyopathy

- HOCM (n = 3)
- LVNC (n = 1)
- DCM (n = 1)

Valvular disease

- Mod AR (n = 1)
- AVR (n = 3)

Miscellaneous

- Atrial fibrillation (n = 5)
- Image artefact* (n = 1)

**Final study size
(n = 130)**

Table 1. Demographic, ECG and left atrial data for all subjects and obesity subgroups

	All (n = 130)	Non-obese (n = 63)	Obese (n = 67)	P-value
Demographic				
Age (year)	51 ± 15	51 ± 17	52 ± 14	= 0.76
Gender (% male)	47	52	42	= 0.23
BMI (kg/m ²)	31 ± 6	27 ± 3	35 ± 5	< 0.0001 *
Office SBP (mmHg)	171 ± 29	173 ± 29	170 ± 30	= 0.57
Office DBP (mmHg)	97 ± 15	98 ± 16	97 ± 14	= 0.73
ESH/ESC BP Grade 1 (%)	20	21	19	= 0.86
ESH/ESC BP Grade 2 (%)	22	22	21	= 0.86
ESH/ESC BP Grade 3 (%)	41	41	40	= 0.91
ACEi / ARB (%)	75	73	76	= 0.69
CCB (%)	53	51	55	= 0.62
ECG data				
P > 110ms (%)	9	10	9	= 0.91
P mitrale (%)	1	2	0	= 0.30
P wave axis < 30° (%)	27	21	33	= 0.12
NPTF-V1 >40ms.mm (%)	17	11	22	= 0.09
PPTF-aVL >0.5mm (%)	9	6	10	= 0.41
Any ECG LAE criteria (%)	46	41	51	= 0.28
Left atrial size data				
Absolute LA volume (ml)	99 ± 33	93 ± 28	105 ± 14	< 0.05 *
Indexed LA volume (ml/m ²)	49 ± 15	49 ± 14	48 ± 16	= 0.90
LAE (%)	26	27	25	= 0.84

BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, ESH / ESC = European society of hypertension / European society of cardiology, ACEi = ACE inhibitor, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker, LA = left atrial, LAE = left atrial enlargement

Table 2. Diagnostic performance of the various ECG parameters at detecting left atrial enlargement. (LAE = left atrial enlargement, ROC-AUC = receiver operator curve-area under curve, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive values, ACC = accuracy)

	Prevalence ECG LAE (%)	ROC-AUC (95 th CI)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	ACC (%)
P > 110 ms	9	0.497 (0.384 – 0.610)	9	91	25	74	69
P mitrale	1	0.495 (0.382 – 0.608)	0	99	0	74	73
P axis < 30°	27	0.437 (0.328 – 0.546)	18	70	17	71	56
NPTF-V1 > 40 ms.mm	17	0.465 (0.355 – 0.576)	12	81	18	72	63
PPTF-aVL > 0.5 mm	8	0.502 (0.389 – 0.616)	9	92	27	74	70
Any ECG criteria for LAE	46	0.387 (0.279 – 0.495)	29	48	17	65	43

Table 3. Obesity subgroup analysis of diagnostic performance of the various ECG parameters at detecting left atrial enlargement. (LAE = left atrial enlargement, ROC-AUC = receiver operator curve-area under curve, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive values, ACC = accuracy)

	Prevalence ECG LAE (%)	ROC-AUC (95 th CI)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	ACC (%)
P > 110 ms							
Non-obese	10	0.515 (0.352 – 0.679)	12	91	33	74	70
Obese	9	0.519 (0.357 – 0.681)	12	92	33	75	72
P mitrale							
Non-obese	2	0.529 (0.364 – 0.695)	0	98	0	74	73
Obese	0	0.500 (0.340 – 0.660)	0	100	0	75	75
P axis < 30°							
Non-obese	21	0.560 (0.395 – 0.725)	29	83 *	38 *	76	68
Obese	34	0.467 (0.309 – 0.625)	29	64	22	73	55
NPTF-V1 > 40 ms.mm							
Non-obese	11	0.504 (0.342 – 0.667)	12	89	29	73	68
Obese	21	0.478 (0.320 – 0.636)	18	78	21	74	63
PPTF-aVL > 0.5 mm							
Non-obese	6	0.537 (0.371 – 0.703)	12	96	50 *	75	73
Obese	10	0.469 (0.314 – 0.625)	6	88	14	73	67
Any ECG criteria for LAE							
Non-obese	41	0.620 (0.462 – 0.778)	59	65 *	38 *	81	63 *
Obese	51	0.475 (0.315 – 0.635)	47	48	24	73	48

* Non-obese vs Obese, P < 0.05

Table 4: Absolute and index left atrial volume in all subjects, non-obese subjects and obese subjects with positive and negative ECG criteria for LAE. (+ve = positive, -ve = negative, LAV = left atrial volume)

	All (n = 130)			Non-obese (n = 63)		Obese (n = 67)		P-value
	(+ve) ECG	(-ve) ECG	P-value	(+ve) ECG	(-ve) ECG	(+ve) ECG	(-ve) ECG	
P wave > 110ms (n)	12	118		6	57	6	61	
LAV (ml)	96 ± 33	99 ± 33	= 0.70	92 ± 30	93 ± 28	99 ± 39	106 ± 36	< 0.05 *
Index LAV (ml/m²)	46 ± 15	49 ± 15	= 0.60	49 ± 16	49 ± 14	44 ± 14	49 ± 16	= 0.89
P mitrale (n)	1	129		1	62	0	67	
LAV (ml)	94	99 ± 33	= 0.89	94	93 ± 28	...	105 ± 36	< 0.05 *
Index LAV (ml/m ²)	52	49 ± 15	= 0.82	52	49 ± 14		48 ± 16	= 0.97
P wave axis < 30° (n)	35	95		13	50	22	45	
LAV (ml)	99 ± 31	99 ± 34	= 0.98	98 ± 33	91 ± 27	99 ± 30	108 ± 39	< 0.05 *
Index LAV (ml/m ²)	48 ± 16	49 ± 15	= 0.74	51 ± 17	48 ± 13	46 ± 15	50 ± 16	= 0.72
NPTF-V1 > 40ms.mm (n)	22	108		7	56	15	52	
LAV (ml)	94 ± 32	100 ± 33	= 0.43	87 ± 8	93 ± 30	97 ± 38	107 ± 36	< 0.05 *
Index LAV (ml/m ²)	46 ± 14	49 ± 15	= 0.32	48 ± 8	49 ± 15	45 ± 16	50 ± 15	= 0.74
PPTF-aVL > 0.5 mm (n)	11	119		4	59	7	60	
LAV (ml)	92 ± 32	100 ± 33	= 0.46	90 ± 29	93 ± 28	93 ± 36	106 ± 36	< 0.05 *
Index LAV (ml/m ²)	45 ± 16	49 ± 15	= 0.37	48 ± 18	49 ± 14	43 ± 16	49 ± 16	= 0.78

* Obese (-ve) ECG vs Non-obese (-ve) ECG P < 0.05

Table 5: Multivariate predictors of false positive and false negative ECGs for left atrial enlargement. (ECG = electrocardiogram, LAE = left atrial enlargement, CI = confidence interval, BMI = body mass index)

	Predictors of false positive ECG for LAE		Predictors of false negative ECG for LAE	
	β -coefficient (95% CI)	P-value	β -coefficient 95% CI	P-value
P wave >110ms				
Age (years)	1.03 (0.98 – 1.08)	= 0.23	1.00 (0.90 – 1.11)	= 0.99
Male gender	1.78 (0.41 – 7.64)	= 0.44	0.34 (0.02 – 5.83)	= 0.46
BMI (kg/m ²)	1.02 (0.90 – 1.15)	= 0.80	0.78 (0.57 – 1.07)	= 0.12
P wave axis <30°				
Age (years)	1.03 (1.00 – 1.07)	= 0.05	1.02 (0.95 – 1.08)	= 0.66
Male gender	0.25 (0.09 – 0.67)	< 0.01 *	2.23 (0.32 – 15.76)	= 0.42
BMI (kg/m ²)	1.11 (1.02 – 1.21)	< 0.05 *	1.02 (0.47 – 1.24)	= 0.82
NPTF-V1 > 40ms·mm				
Age (years)	1.00 (0.97 – 1.03)	= 0.89	0.99 (0.90 – 1.09)	= 0.82
Male gender	2.67 (0.86 – 8.25)	= 0.09	0.18 (0.01 – 2.81)	= 0.22
BMI (kg/m ²)	1.02 (0.93 – 1.11)	= 0.68	0.78 (0.59 – 1.05)	= 0.10
PPTF-aVL >0.5mm				
Age (years)	0.98 (0.93 – 1.03)	= 0.49	1.02 (0.93 – 1.11)	= 0.75
Male gender	0.24 (0.04 – 1.33)	= 0.10	2.23 (0.16 – 31.33)	= 0.55
BMI (kg/m ²)	1.05 (0.92 – 1.19)	= 0.31	0.89 (0.70 – 1.14)	= 0.36